You Position: Home > Paper

Progress in iron chelators: the report of the 53rd annual meeting of American Society of Hematology

( views:458, downloads:160 )
Author:
No author available
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
2
DOI:
10.3760/cma.j.issn.1009-9921.2012.02.004
Key Word:
铁螯合剂;血液病;美国血液学会年会;Iron chelating agents;Hematologic disease;American Society of Hematology annual meeting

Abstract: Chelation therapy could remove transfusional iron burden. Three chelators are currently available, including deferoxamine, deferiprone, and deferasirox, which can be used as monotherapy or in combination. Several factors must be considered in the design of optimal and individualized chelation regimens,which include chelator availability and its properties,degree of organ-specific iron loading,ongoing transfusional iron burden, and patient preference. Comparative effectiveness trials may help to determine the ideal strategy. This article reviews latest research presented at the 53rd annual meeting of the American Society of Hematology (ASH) on the use of iron chelators.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn